SPRY (ARS Pharmaceuticals, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by SPRY officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-02 | Margaret Ekins Smith | Chief Commercial Officer | A | — | — |
| 2026-07-02 | Donn Casale | President | A | — | — |
| 2026-06-26 | BRENT L SAUNDERS | Director | A | — | — |
| 2026-06-26 | Laura Shawver | Director | A | — | — |
| 2026-06-26 | Saqib Islam | Director | A | — | — |
| 2026-06-26 | Michael Kelly | Director | A | — | — |
| 2026-06-26 | PHILLIP M SCHNEIDER | Director | A | — | — |
| 2026-06-26 | Peter A. Thompson | Director | A | — | — |
| 2026-06-26 | Rajeev Dadoo | Director | A | — | — |
| 2026-06-26 | Pratik Shah | Director | A | — | — |
| 2026-06-26 | RA Capital Healthcare Fund LP | Director | A | — | — |
| 2026-06-12 | Alexander A Fitzpatrick | Chief Legal Officer | Sell | — | — |
| 2026-06-12 | Eric Karas | Chief Commercial Officer | MIXED | — | — |
| 2026-01-05 | Kathleen D. Scott | Chief Financial Officer | A | — | — |
| 2026-01-05 | Justin Chakma | Chief Business Officer | A | — | — |
| 2026-01-05 | Brian Dorsey | Chief Operating Officer | A | — | — |
| 2026-01-05 | Eric Karas | Chief Commercial Officer | A | — | — |
| 2026-01-05 | Alexander A Fitzpatrick | Chief Legal Officer | A | — | — |
| 2026-01-05 | Richard E Lowenthal | PRESIDENT AND CEO | A | — | — |
| 2026-01-05 | Sarina Tanimoto | CHIEF MEDICAL OFFICER | A | — | — |
| 2025-11-14 | Justin Chakma | Chief Business Officer | MIXED | — | — |
| 2025-11-14 | Pratik Shah | Director | G | — | — |
| 2025-11-14 | Brian Dorsey | Chief Operating Officer | MIXED | — | — |
| 2025-08-22 | Richard E Lowenthal | PRESIDENT AND CEO | Sell | — | — |
| 2025-08-22 | Kathleen D. Scott | Chief Financial Officer | MIXED | — | — |
| 2025-08-21 | Sarina Tanimoto | CHIEF MEDICAL OFFICER | Sell | — | — |
| 2025-07-03 | Eric Karas | Chief Commercial Officer | MIXED | — | — |
| 2025-07-01 | Deerfield Mgmt III, L.P. | 10%+ Owner | Sell | — | — |
| 2025-06-27 | PHILLIP M SCHNEIDER | Director | A | — | — |
| 2025-06-27 | Laura Shawver | Director | A | — | — |
| 2025-06-27 | Saqib Islam | Director | A | — | — |
| 2025-06-27 | Pratik Shah | Director | A | — | — |
| 2025-06-27 | Peter A. Thompson | Director | A | — | — |
| 2025-06-27 | Rajeev M. Shah | Director | A | — | — |
| 2025-06-27 | Rajeev Dadoo | Director | A | — | — |
| 2025-06-27 | BRENT L SAUNDERS | Director | A | — | — |
| 2025-06-27 | Michael Kelly | Director | A | — | — |
| 2025-06-20 | Eric Karas | Chief Commercial Officer | MIXED | — | — |
| 2025-05-22 | BRENT L SAUNDERS | Director | MIXED | — | — |
| 2025-05-22 | Kathleen D. Scott | Chief Financial Officer | MIXED | — | — |
| 2025-05-22 | Alexander A Fitzpatrick | Chief Legal Officer | MIXED | — | — |
| 2025-04-08 | Laura Shawver | Director | MIXED | — | — |
| 2025-03-21 | Eric Karas | Chief Commercial Officer | MIXED | — | — |
| 2025-03-07 | Laura Shawver | Director | MIXED | — | — |
| 2025-02-04 | Laura Shawver | Director | MIXED | — | — |
| 2025-01-07 | Laura Shawver | Director | MIXED | — | — |
| 2025-01-03 | Eric Karas | Chief Commercial Officer | A | — | — |
| 2025-01-03 | Justin Chakma | Chief Business Officer | A | — | — |
| 2025-01-03 | Kathleen D. Scott | Chief Financial Officer | A | — | — |
| 2025-01-03 | Alexander A Fitzpatrick | Chief Legal Officer | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | PRESIDENT AND CEO | 13,186,389 | — |
| — | CHIEF MEDICAL OFFICER | 12,292,712 | — |
| — | Director | 9,452,119 | — |
| — | Director | 8,556,774 | — |
| — | Director | 8,019,187 | — |
| — | 10%+ Owner | 7,490,404 | — |
| — | 10%+ Owner | 5,257,329 | — |
| — | 10%+ Owner | 4,887,254 | — |
| — | Director | 4,474,554 | — |
| — | Director | 3,009,677 | — |
| — | Director | 2,106,774 | — |
| — | Director | 902,904 | — |
| — | Director | 269,323 | — |
| — | Director | 269,323 | — |
| — | Director | 260,348 | — |
| — | Chief Business Officer | 136,380 | — |
| — | Chief Legal Officer | 90,910 | — |
| — | Director | 83,225 | — |
| — | Chief Financial Officer | 18,292 | — |
| — | Chief Commercial Officer | 12,176 | — |
| — | Chief Operating Officer | 10,789 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the SPRY quote page; the site-wide leaderboard is on the insider transactions hub.